In the latest trading session, 0.69 million Immunic Inc (NASDAQ:IMUX) shares changed hands as the company’s beta touched 1.85. With the company’s most recent per share price at $1.32 changed hands at -$0.08 or -5.72% at last look, the market valuation stands at $118.89M. IMUX’s current price is a discount, trading about -59.85% off its 52-week high of $2.11. The share price had its 52-week low at $0.97, which suggests the last value was 26.52% up since then. When we look at Immunic Inc’s average trading volume, we note the 10-day average is 0.78 million shares, with the 3-month average coming to 838.81K.

Analysts gave the Immunic Inc (IMUX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMUX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Immunic Inc’s EPS for the current quarter is expected to be -0.24.

Immunic Inc (NASDAQ:IMUX) trade information

Instantly IMUX was in red as seen in intraday trades today. With action 11.86%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -12.01%, with the 5-day performance at 11.86% in the green. However, in the 30-day time frame, Immunic Inc (NASDAQ:IMUX) is 10.92% up. Looking at the short shares, we see there were 3.8 million shares sold at short interest cover period of 2.96 days.

The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 73.6% from its recent market value. According to analyst projections, IMUX’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -278.79% plunge from its current level, while the stock would need to soar -278.79% for it to hit the projected low.

Immunic Inc (IMUX) estimates and forecasts

Data shows that the Immunic Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 9.08% over the past 6 months, a 53.08% in annual growth rate that is considerably higher than the industry average of 17.60%.

According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 31.12%. The 2024 estimates are for Immunic Inc earnings to increase by 54.30%, but the outlook for the next 5-year period is at 15.50% per year.

IMUX Dividends

Immunic Inc is expected to release its next quarterly earnings report in January.

Immunic Inc (NASDAQ:IMUX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 3.44% of Immunic Inc shares while 64.85% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 67.16%. There are 64.85% institutions holding the Immunic Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 9.15% of the shares, roughly 8.9 million IMUX shares worth $9.88 million.

AVIDITY PARTNERS MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.15% or 8.9 million shares worth $9.88 million as of 2024-06-30.

Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund. With 1.87 shares estimated at $2.48 million under it, the former controlled 2.08% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.85% of the shares, roughly 1.67 shares worth around $2.21 million.